Multiple Myeloma


Share

Program Content

Activities

DREAMM 7 Belantamab Combo
DREAMM-7 Efficacy Update: Belantamab Mafodotin Plus Bortezomib, Dexamethasone vs Daratumumab Plus Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation